Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of Biopharmaceuticals

The success of personalized medicine in oncology relies on using highly effective and precise therapeutic modalities such as small interfering RNA (siRNA) and monoclonal antibodies (mAbs). Unfortunately, the clinical exploitation of these biological drugs has encountered obstacles in overcoming intr...

Full description

Saved in:
Bibliographic Details
Published in:Advanced materials (Weinheim) 2024-04, Vol.36 (14), p.e2309355-n/a
Main Authors: López‐Estévez, Ana María, Lapuhs, Philipp, Pineiro‐Alonso, Laura, Alonso, María José
Format: Article
Language:English
Subjects:
cancer
Customization
intracellular
Monoclonal antibodies
monoclonal antibody
nanotechnology
RNA
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The success of personalized medicine in oncology relies on using highly effective and precise therapeutic modalities such as small interfering RNA (siRNA) and monoclonal antibodies (mAbs). Unfortunately, the clinical exploitation of these biological drugs has encountered obstacles in overcoming intricate biological barriers. Drug delivery technologies represent a plausible strategy to overcome such barriers, ultimately facilitating the access to intracellular domains. Here, an overview of the current landscape on how nanotechnology has dealt with protein corona phenomena as a first and determinant biological barrier is presented. This continues with the analysis of strategies facilitating access to the tumor, along with conceivable methods for enhanced tumor penetration. As a final step, the cellular barriers that nanocarriers must confront in order for their biological cargo to reach their target are deeply analyzed. This review concludes with a critical analysis and future perspectives of the translational advances in personalized oncological nanomedicine. This review discovers how RNA and mAbs are shaping the future of personalized cancer nanomedicine. This also dives into the current landscape and nanotechnology's battle with protein corona phenomena, explores strategies for enhanced tumor access and penetration, and confronts the cellular barriers that nanocarriers must conquer to reach intracellular domains. Perspectives on the remaining challenges and potential prospects are discussed.
ISSN:0935-9648
1521-4095
DOI:10.1002/adma.202309355